Akorn Inc (AKRX) 30.25 $AKRX Technical Analysis on Drugs

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Akorn Inc (AKRX) 30.25 $AKRX

Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 12.87 (-0.13), CPRX: 0.62 (-0.03), AKRX: 30.25 (-0.55), PCRX: 44.07 (-1.34)

Akorn Updates Form S-8 Status by Filing Form 10-Q's for First, Second and Third Quarters of 2015
GlobeNewswire - Thu Jun 02, 5:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it has filed quarterly reports on Forms 10-Q with the Securities and Exchange Commission (SEC) for the quarters ended March 31, 2015, June 30, 2015 and September 30, 2015. The quarterly financial results that are included in the individual Forms 10-Q were previously filed by the Company in its comprehensive Form 10-K for the fiscal year 2015 that was filed with the SEC on May 10, 2016. The individual Forms 10-Q were filed solely in order to make effective the Company's Registration Statement on Form S-8, on which the Company's securities offered under its employee benefit plan are registered.
AKRX: 30.25 (-0.55)

Akorn to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue May 31, 7:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that management will be presenting at the Jefferies 2016 Healthcare Conference and William Blair 36th Annual Growth Stock Conference in June.
AKRX: 30.25 (-0.55)

SmarTrend Watching for Potential Rebound in Shares of Akorn After 2.24% Loss
Comtex SmarTrend(R) - Thu May 26, 2:05PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $29.37 to a high of $30.51. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $30.27 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AKRX: 30.25 (-0.55)

Akorn (AKRX) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:54AM CDT
As of late, it has definitely been a great time to be an investor in Akorn, Inc. (AKRX)
AKRX: 30.25 (-0.55)

Watch for Akorn to Potentially Pullback After Gaining 7.19% Yesterday
Comtex SmarTrend(R) - Tue May 17, 1:24PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $27.90 to a high of $30.39. Yesterday, the shares gained 7.2%, which took the trading range above the 3-day high of $28.19 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 30.25 (-0.55)

Akorn meets 1Q profit forecasts
Automated Insights - Mon May 16, 4:03PM CDT
LAKE FOREST, Ill. (AP) _ Akorn Inc. (AKRX) on Monday reported first-quarter earnings of $41.9 million.
AKRX: 30.25 (-0.55)

SmarTrend Watching for Potential Pullback in Shares of Akorn After 14.34% Gain
Comtex SmarTrend(R) - Tue May 10, 3:26PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $24.43 to a high of $26.81. Yesterday, the shares gained 14.3%, which took the trading range above the 3-day high of $24.43 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 30.25 (-0.55)

Teva's (TEVA) Stock Gains on Q1 Earnings & Revenue Beat
Arpita Dutt - Zacks Investment Research - Tue May 10, 6:18AM CDT
2016 is a transition year for Teva (TEVA) as it works on the integration of Actavis Generics and progresses with its branded pipeline.
AKRX: 30.25 (-0.55), TEVA: 53.01 (-0.30), AMPH: 16.13 (-0.30), NVS: 78.94 (-1.57)

Relypsa Soars 67% in Thursday Trading on Buyout Rumors
Arpita Dutt - Zacks Investment Research - Fri Apr 08, 8:50AM CDT
Relypsa (RLYP) shoots up on rumors that the company will be acquired.
AKRX: 30.25 (-0.55), RLYP: 19.34 (+0.48), AZN: 27.97 (-0.99), AMPH: 16.13 (-0.30)

3 Value Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 24, 8:21AM CDT
Image source: Pixabay. While many companies' shares are rising past their fair values now, others are trading at potentially bargain prices. The difficulty with bargain shopping, though, is that you may be understandably hesitant to buy stocks...
AKRX: 30.25 (-0.55), AMCX: 60.36 (-0.63), ICE: 261.29 (-1.23)

3 Beaten-Up Healthcare Stocks: Are They Bargains?
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 22, 9:26PM CDT
SOURCE: FLICKR USER ELLIOTT BROWN. A sharp sell-off in healthcare stocks has left many investors licking their wounds, but other investors might be licking their chops. With many healthcare stocks trading at their lowest valuation in years, the...
JNJ: 117.01 (+0.01), VRX: 24.14 (-1.34), AKRX: 30.25 (-0.55), DEPO: 19.82 (-0.81)

Transocean and Royal Caribbean slump, Wynn and Staples rise
AP - Tue Mar 22, 3:53PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq stock market:
SPLS: 8.71 (-0.04), ESRX: 75.91 (-1.02), RCL: 73.93 (-2.31), RIG: 10.75 (-0.72), AKRX: 30.25 (-0.55), WYNN: 100.45 (-0.34), ODP: 3.50 (-0.02), MFRM: 29.40 (-4.18), MS: 25.54 (-0.54)

Why Akorn, Inc. Is Soaring 39% Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 22, 12:33PM CDT
Image source: Akorn, Inc. What: Following the release of its preliminary fourth-quarter and full-year financials, shares in Akorn  (NASDAQ: AKRX) are rallying 39.05% at 1:00 p.m. Tuesday.  So what: The mid-sized generic pharmaceutical...
AKRX: 30.25 (-0.55)

Look for Shares of Akorn to Potentially Pullback after Yesterday's 36.93% Rise
Comtex SmarTrend(R) - Tue Mar 22, 11:59AM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $21.78 to a high of $26.26. Yesterday, the shares gained 36.9%, which took the trading range above the 3-day high of $21.23 on volume of 8.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 30.25 (-0.55)

Akorn Receives Expected Additional Delinquency Notice From Nasdaq
GlobeNewswire - Mon Mar 07, 6:00AM CST
Akorn, Inc. (Nasdaq:AKRX) today announced that, as expected, it has received a notice from the Nasdaq Listing Qualifications Staff stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company did not timely file its Form 10-K for the year ended December 31, 2015 with the Securities and Exchange Commission (SEC) by February 29, 2016.
AKRX: 30.25 (-0.55)

Akorn Has Returned 20.2% Since SmarTrend Recommendation (AKRX)
Comtex SmarTrend(R) - Fri Feb 05, 10:52AM CST
SmarTrend identified a Downtrend for Akorn (NASDAQ:AKRX) on January 12th, 2016 at $31.33. In approximately 3 weeks, Akorn has returned 20.20% as of today's recent price of $25.00.
AKRX: 30.25 (-0.55)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 52

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 28

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 36

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 46

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 63

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 38

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 40

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading

Top 5 Most Recently Viewed Articles

Peter Schiff's Insights: The Golden Edge Over Stocks

Updated Category News Views 256

Gold's Decades-Long Dominance Over Equities Peter Schiff, a well-known economist, emphasizes the impressive performance of gold over equities for nearly 60 years. He notes that even though the Dow Jones has seen a near 50-fold increase since 1966, gold has considerably outperformed equities, achieving a remarkable 120-fold increase in value during the same timeframe. In...

Continue Reading
Exploring Hidden Wealth: Jim Rickards' Insights on U.S. Resources

Updated Category News Views 392

Revealing America’s Abundant Untapped Resources As discussions sharpen over financing significant economic initiatives tied to President Trump's administration, intriguing insights have resurfaced. A presentation from economic strategist Jim Rickards has drawn attention for proposing that the U.S. may possess essential resources that could be leveraged to support these...

Continue Reading
Middle West Spirits Welcomes Old Elk Distillery to Its Family

Updated Category News Views 344

Middle West Spirits Expands National Footprint Middle West Spirits, a prominent name in the distilling world, has recently taken significant steps forward by acquiring Old Elk Distillery, celebrated for its exceptional whiskeys. This union not only adds to Middle West Spirits' impressive portfolio but also signifies a promising collaboration that aims to take the whiskey...

Continue Reading
Citi Downgrades Kering: Insights on Brand Challenges

Updated Category News Views 57

Citi Downgrades Kering: Insights on Brand Challenges Recently, Citi took action regarding Kering (EPA:PRTP) by adjusting its stock recommendation from Buy to Neutral. Along with changing the stock rating, a revised price target was also set at €264.00, lowered from an earlier target of €350.00. This decision reflects the increasing difficulties the luxury goods...

Continue Reading
Apple's Steps forward to Rescind iPhone Sales Ban in Indonesia

Updated Category News Views 155

Apple Inc's Negotiations to Lift iPhone Sales Ban Apple Inc (NASDAQ: AAPL) is making notable strides in its efforts to resolve the recent ban on iPhone sales imposed by the Indonesian government. Reports indicate that the tech giant is on the verge of finalizing an agreement that could lead to the lifting of this restriction, as confirmed by a government minister familiar...

Continue Reading